Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 17/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31578493 | 1.00 | PTGS2 (0.48) | PTGS2HSD11B1PTGS1CA1CA2 | |
| SCHEMBL31578498 | 0.84 | PTGS2 (0.51) | PTGS2PTGS1 | |
| SCHEMBL25363328 | 0.84 | PTGS2 (0.51) | PTGS2PTGS1 | |
| SCHEMBL30899910 | 0.80 | HSD11B1 (0.49) | PTGS2HSD11B1PTGS1CA1CA2 | |
| SCHEMBL30899903 | 0.80 | HSD11B1 (0.49) | PTGS2HSD11B1PTGS1CA1CA2 | |
| SCHEMBL25365945 | 0.79 | PTGS2 (0.48) | PTGS2HSD11B1PTGS1 | |
| SCHEMBL31229264 | 0.79 | PTGS2 (0.48) | PTGS2HSD11B1PTGS1 | |
| SCHEMBL25367493 | 0.78 | PTGS2 (0.42) | PTGS2PTGS1CA1CA2CA12 | |
| SCHEMBL29395846 | 0.78 | PTGS2 (0.41) | PTGS2HSD11B1PTGS1 | |
| SCHEMBL26072684 | 0.78 | PTGS2 (0.41) | PTGS2HSD11B1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4479407-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | Bristol-Myers Squibb Company (US) | 2024-12-25 | — | — | EP | disclosed |
| WO-2023159153-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-24 | — | — | WO | disclosed |